Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants

NCT06787144 is registered in ClinicalTrials.gov with Enliven Therapeutics as lead sponsor.

NCT NCT06787144
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06787144 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants
Lead sponsor
Enliven Therapeutics
Phase
Phase 1
Overall status
Recruiting
Start date
January 23, 2025
Completion date
January 31, 2028
Enrollment
21 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

chronic phase cml, cml (chronic myelogenous leukemia)